There is significant evidence for genetic factors in the susceptibility to anorexia nervosa (AN). Previously genetic variation in the estrogen receptor 2 gene (ESR2) has been studied, however no strong evidence of association with AN has been found. In the present study variation in the estrogen receptor 1 (ESR1) and ESR2 genes was examined. Estrogen receptors have been localised to areas of the brain involved in behaviour and regulation of food intake. The anorexic effects of estrogen are accentuated by stress and thus it is postulated that variation in the estrogen receptors may contribute to the genetic susceptibility to AN in females. A cohort of 170 female, Caucasian AN sufferers and 152 female controls were typed for dinucleotide repeat polymorphisms in both ESR1 and ESR2 and two further SNPs at each locus. Variation at ESR1 was not associated with AN. However an association was found at the ESR2 locus with the heterozygous genotype of the G1082A polymorphism and AN but not with any of the other ESR2 polymorphisms analysed. Analysis of haplotypes at ESR1 and ESR2 showed no significant evidence of association with AN suggesting that the variability in ESR2 alone may contribute to the genetic susceptibility to AN.
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More than 90% of AN sufferers are female. It is generally accepted that the age of onset of AN shows a bimodal distribution 1 with one peak at or around the age of puberty in females when estrogen levels are dramatically increased. Estrogen receptors in the brain colocalise with corticotrophin releasing factor (CRF) 2 suggesting an interaction between estrogen and CRF may modulate the hypothalamic pituitary adrenal (HPA) axis. The disruption of the HPA axis in AN sufferers cannot be wholly attributed to the effects of semi-starvation 3 and the HPA axis is also elevated in response to stress. 4, 5 In rodents and primates high estrogen levels are known to have an inhibitory effect on food intake. 6 This led us to postulate that estrogen may be involved in the genetic disposition to AN. Estrogen interacts in both the periphery and the central nervous system via at least two different estrogen receptors (ESR1 and ESR2). 7, 8 Previously Rosenkranz et al reported genetic variations in the ESR2 (ESR-beta) gene in probands of different weight extremes (including patients with AN and bulimia nervosa) and reported suggestive evidence of an association with susceptibility to AN.
9 ESR1 has been shown to play a role in behaviour in mice 10 and more recently variants of the ESR1 gene have been implicated in anxiety.
11
As it has previously been suggested that anxiety may accentuate the anorexic effects of estrogen, 12 we postulate that the interaction of stress and estrogen may modulate the HPA axis in the pathogenesis of anorexia nervosa. Both ESR1 and 2 are localised to the amygdaloid complex, 13 an area known to be critical in the control of emotions. These receptors are known to form heterodimers in vitro 14 and therefore this study aimed to investigate the combined effect of genetic variation in both the ESR1 and ESR2 genes in the genetic susceptibility to AN.
In the present study, 170 AN sufferers and 152 control subjects were genotyped for a highly polymorphic dinucleotide repeat 11 and two previously described SNPs (PvuII restriction fragment length polymorphism (RFLP) 15 and XbaI RFLP 16 ) located in exon 2 of the ESR1 gene. At the ESR2 locus the genotype of each individual was determined at a dinucleotide repeat 17 and two previously described SNPs (G1082A and A1730G) located in exon 5 and 8 respectively. 9 The distribution of the alleles at the dinucleoide repeat ESR1 in the control and AN populations is shown in Figure 1 . Statistical analysis using the 'Clump' 19 computer package fails to show any signifi- cant difference in the distribution of alleles between the AN and control population ( 2 = 8.04, P Ͼ 0.2, df = 18). Previous studies using this microsatellite have suggested a rationale for dividing the alleles into two groups, or modes, representing short alleles (S) (alleles 1-12) and long alleles (L) (alleles [13] [14] [15] [16] [17] [18] [19] . 11 Analysis of our data in this way still failed to show any association with AN ( 2 = 2.60, P Ͼ 0.2, df = 2). The RFLP alleles at ESR1 were represented as P or p (PvuII) and X or x (XbaI) with capital letters signifying the absence of and small letters the presence of the restriction site. A PvuII-XbaI haplotype was constructed for each subject. There was no significant difference between the case and control populations (genotype and constructed haplotype frequencies shown in Table 1 ).
Analysis of the dinucleotide repeat at ESR2 observed 10 of the 15 alleles previously described. 17 The allele frequencies did not differ between the AN and control populations ( Figure 2) . Analysis of the SNPs in ESR2 did, however, demonstrate a significant overrepresentation of the heterozygous genotype of G1082A in the AN population (Table 1, 2 = 8.65, P = 0.003, pc = 0.006, df = 2).
As it has been postulated that ESR1 and ESR2 may interact, 14 we investigated whether variation at both loci may have a combined effect in the susceptibility to AN. A haplotype analysis was carried out for each of the SNPs studied (except for G1082A which was not suitable for analysis due to its low heterogeneity) and at the two dinucleotide repeat markers. Haplotype frequencies constituted from the genotype at the ESR1 dinucleotide repeat, XbaI RFLP in ESR1, the ESR2 dinucleotide repeat and the ESR2 SNP A1730G (1 3 4 5, Table 2 ) differed significantly (P Ͻ 0.05) between the AN and control population. However, when multiple testing is taken into account the results are no longer significant.
In the present study there is no evidence of variation at the ESR1 locus contributing to the genetic susceptibility to AN. Construction of haplotypes of ESR1 and ESR2 does not suggest any interaction between these two loci in the pathology of anorexia nervosa. However the two SNPs studied at the ESR2 locus have previously been investigated in an AN population. 9 This study does not replicate the findings of Rosenkrantz et al 19 for suggestive evidence for association of the 1082G allele (nominal P value = 0.04) with AN, 8 conversely this study reports an association with the heterozygous genotype G1082A. The present study observed an increased frequency of the 1082A allele in the AN population ( 2 = 11.46, P = 0.0007, df = 1) which results in the genotype frequencies in this population alone deviating from Hardy-Weinberg equilibrium. This was not seen in the earlier study. A posthoc power analysis 20 based on the observation that the susceptibility allele has a frequency of 10% in the AN population and a genotype relative risk of 3 predicts that this study has 70% power to detect this effect at the 5% significance level. Also given the low frequency of the 1082A allele and the discrepancies between the two studies, replication in a larger cohort is necessary in order to verify these findings. Rosenkrantz's study 9 was based on a German population whereas this study sampled British white Caucasians therefore the differences may arise from genetic heterogeneity between these populations.
There is no obvious functional implication of the G1082A polymorphism. However this polymorphism may be in linkage disequilibrium with an as yet unidentified functionally important mutation within Column 1 shows the loci in each haplotype: Locus 1 = dinucleotide repeat at ESR1 (subdivided into two groups-alleles 1-12, 14-19); locus 2 = PvuII RFLP in ESR1; locus 3 = XbaI RFLP in ESR1; locus 4 = dinucleotide repeat at ESR2 (subdivided into two groups-alleles 1-6, 7-12); and locus 5 = A1730G in ESR2. Therefore haplotype '1 2' considers the variation at the ESR1 dinucleotide repeat and the PvuII RFLP in ESR1. Numbers in parentheses indicate the empirical P-value.
the ESR2 gene. Although the role of the ESR2 gene cannot be excluded in the susceptibility to AN without any supporting evidence, the most likely explanation of the significant association seen in this study is that it is a false positive.
Methods
A cohort of 170 British Caucasian female AN sufferers (DSM-IV criteria) were obtained from the clinics of Dr Pieri. Mean age of disease onset of this group was 18.1 years with a minimum average body mass index (BMI) of 13.73 kg m −2 during illness. The control cohort of 152 normal females was obtained from a number of sources. Mean age of the controls was 30.28 years with an average BMI of 22.02 kg m −2 . The latter were screened by questionnaire (adapted from EDI 21 ) for a personal or immediate family history of an eating disorder or other psychiatric illness.
All individuals from both cohorts were asked to complete identical questionnaires (based on the EDI 21 ) covering demographic data, eating history, a history of their height and weight, menstrual history, personal and family history, and psychiatric history. These were independently assessed before inclusion into the study.
Where questionnaire answers were not fully informative or ambiguous, individuals also received a standard diagnostic interview and diagnoses were based on all available clinical information (including interview, case notes and questionnaire). Written informed consent was obtained. Approval for this study was provided by the Leeds (East) Medical Research (Ethics) Committee.
Genotyping
Genomic DNA was prepared from peripheral venous blood samples by use of standard protocols. The dinucleotide repeat regions of ESR1 and ESR2 were amplified using fluorescently labelled primers the sequence of which has been previously described. 11, 16 The allele size (ESR1 215 bp for allele No. 1, 183 bp for allele No. 17 and ESR2 150 bp for allele 1 and 178 bp for allele 15) was determined by use of the ABI 377 and Genotyper (version 1.1) (PE Applied Biosystems, UK).
Statistics
Statistical analysis was performed, using 'Clump', 19 to identify any differences between allele frequencies in the control and the AN populations. Haplotype analysis was performed by Daniela Markovic in collaboration with Jurg Ott, Rockefeller University, USA using EHplus. 22, 23 The approach is to estimate haplotype frequencies and compute corresponding log likelihoods three times: (1) for cases (L 1 = log likelihood); (2) for controls (L 2 ); and (3) for cases and controls combined (L 3 ). The quantity X 2 = 2(L 1 + L 2 − L 3 ) approximately follows a chi-square distribution when there is no association. Significance levels (P) were initially based on the chi-square approximation to the likelihood ratio test. For small P-values, the permutation procedure built into EHplus was used to obtain empirical estimates of statistical significance (this was done only for few values because the permutation procedure is quite time-consuming). The microsatellites at ESR1 and ESR2 were divided into two groups for haplotype analysis (alleles 1-12 and 13-19 and alleles 1-6 and 7-12 at ESR1 and ESR2 respectively) to reduce the number of haplotypes. Corrected P values (pc) where given correspond to Bonferroni corrections calculated by multiplying the observed P value by the number of alleles/genotypes minus 1.
